Clinical feature |
No. |
DAPK1
unmethylated |
% |
DAPK1
Methylated |
% |
P value |
Patients |
200 |
109 |
54.5 |
91 |
45.5% |
<0.0001 |
Males |
128 |
62 |
48.4% |
66 |
51.5% |
0.02 |
Female |
72 |
47 |
65.2% |
25 |
34.7% |
CP-CML |
81 |
57 |
70.3% |
24 |
29.6% |
<0.0001 |
AP-CML |
54 |
28 |
51.8% |
26 |
48.1% |
BC-CML |
65 |
24 |
36.9% |
41 |
63.07% |
A2b2 |
59 |
35 |
59.3% |
24 |
40.6% |
0.5 |
A2B3 |
124 |
64 |
51.6% |
60 |
48.3% |
A2b2/ A2b3 |
17 |
10 |
58.8% |
7 |
41.1% |
Imatinib |
200 |
109 |
54.5% |
91 |
45.5% |
|
Age >45 |
71 |
39 |
54.9% |
32 |
45.07% |
0.9 |
Age <45 |
129 |
70 |
54.2% |
59 |
45.7% |
MMR |
50 |
31 |
62% |
19 |
38% |
0.4 |
No MR |
150 |
78 |
52% |
72 |
48% |
MHR |
30 |
20 |
66.6% |
10 |
33.3% |
0.02 |
Minor HR |
46 |
29 |
63.04 |
17 |
36.9% |
Loss HR |
124 |
60 |
48.3% |
64 |
51.6% |
Thrombocytopenia |
100 |
52 |
52 |
48 |
48% |
0.5 |
|